Inovio Pharmaceuticals (GBM) Ownership - Who Owns Inovio Pharmaceuticals?
Inovio Pharmaceuticals (GBM) Ownership Overview
- 0.38% Insiders
- 14.30% Mutual Funds
- 0.29% Other Institutional Investors
- 4.70% ETFs
- 80.34% Public Companies and Individual Investors
The ownership structure of Inovio Pharmaceuticals (DE:GBM) stock is a mix of institutional, retail, and individual investors. Approximately 19.29% of the company’s stock is owned by Institutional Investors, 0.38% is owned by Insiders, and 80.34% is owned by Public Companies and Individual Investors.
The ownership structure of Inovio Pharmaceuticals (DE:GBM) stock is a mix of institutional, retail, and individual investors. Approximately 19.29% of the company’s stock is owned by Institutional Investors, 0.38% is owned by Insiders, and 80.34% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Fidelity Securities Fund | 10,529,144 | Institution | 10.18% | 8,855,010 |
| Vanguard | 4,512,212 | Institution | 4.36% | 3,794,770 |
| Vanguard Index Funds | 3,563,417 | Institution | 3.45% | 2,996,834 |
| Fidelity Concord Street Trust | 285,565 | Institution | 0.28% | 240,160 |
| Ishares | 254,336 | Institution | 0.25% | 213,897 |
| Bridgeway Funds, Inc. | 173,000 | Institution | 0.17% | 145,493 |
| Thomas E. Claugus | 126,119 | Institution | 0.12% | 106,066 |
| Goldman Sachs Trust | 116,762 | Institution | 0.11% | 98,197 |
| Jacqueline Elizabeth Shea | 111,021 | Insider | 0.11% | 93,369 |
| Invesco | 90,933 | Institution | 0.09% | 76,475 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Fidelity Securities Fund | 10,529,144 | Institution | 10.18% | 8,855,010 |
| Vanguard Index Funds | 3,563,417 | Institution | 3.45% | 2,996,834 |
| Fidelity Concord Street Trust | 285,565 | Institution | 0.28% | 240,160 |
| Bridgeway Funds, Inc. | 173,000 | Institution | 0.17% | 145,493 |
| Goldman Sachs Trust | 116,762 | Institution | 0.11% | 98,197 |
| Vanguard Valley Forge Funds | 45,128 | Institution | 0.04% | 37,953 |
| Vanguard Institutional Index Funds | 42,017 | Institution | 0.04% | 35,336 |
| Victory Portfolios Iii | 28,563 | Institution | 0.03% | 24,021 |
| John Hancock Variable Insurance Trust | 1,613 | Institution | <0.01% | 1,357 |
| Morgan Stanley Pathway Funds | 950 | Institution | <0.01% | 799 |
FAQ
Who Owns Inovio Pharmaceuticals (DE:GBM)?
According to the latest TipRanks data, approximately 19.29% of the company's stock is held by institutional investors, 0.38% is held by insiders, and 80.34% is held by public companies and individual investors.
What percentage of Inovio Pharmaceuticals (DE:GBM) stock is held by institutional investors?
According to the latest TipRanks data, approximately 19.29% of Inovio Pharmaceuticals (DE:GBM) stock is held by institutional investors: 14.30% by mutual funds, 4.70% by ETFs and 0.29% by other institutional investors.
What percentage of Inovio Pharmaceuticals (DE:GBM) stock is held by retail investors?
According to the latest TipRanks data, approximately 80.34% of Inovio Pharmaceuticals (DE:GBM) stock is held by public companies and individual investors.
Who owns the most shares of Inovio Pharmaceuticals (DE:GBM)?
Fidelity Securities Fund owns the most shares of Inovio Pharmaceuticals (DE:GBM).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.